95
Viatris to acquire Pacira BioSciences for $36.50/share cash
Why it matters
Viatris Inc. and Pacira BioSciences entered into a definitive merger agreement on October 8, 2026, with Viatris acquiring all outstanding shares at $36.50 per share in cash via tender offer followed by statutory merger. The price and structure are now contractually binding, making completion highly probable pending HSR clearance and shareholder-vote-free statutory mechanics under Delaware law.
In plain language
Viatris is buying Pacira for $36.50 per share in cash. This is a done deal subject only to antitrust review, so Pacira stock should trade near that price.
Exposure
PCRX ▲VTRS ·
Price check
not measured: no fresh price at the time of scoringHow this is measured
Information only. AURA does not give buy or sell recommendations.